| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2017-10-03 | Merck KGaA (Germany) | new production line at the manufacturing site of Bari | construction of new premises | Construction of new premises | ||
| 2017-10-03 | Lonza (Switzerland) Shire (UK - USA) | clinical-stage mammalian manufacturing site in Hayward (USA - CA) | plant acquisition | Technology - Services | Plant acquisition | |
| 2017-09-29 | TG Therapeutics (USA - NY) Fast Forward (USA - NY) | TGR-1202 (umbralisib) | progressive multiple sclerosi | clinical research | Neurodegenerative diseases | Clinical research agreement |
| 2017-09-20 | Enterome Bioscience (France) | research laboratories in Genopole | opening of new premises | Autoimmune diseases - Inflammatory diseases - Digestive diseases - Cancer - Oncology | Opening of new premises | |
| 2017-09-18 | Immunocore (UK) Bill and Melinda Gates Foundation (USA) | ImmTAV (Immune mobilising monoclonal TCRs Against Virus) and ImmTAB (Immune mobilising monoclonal TCRs Against Bacteria) therapeutics | HIV infection, tuberculosis | development | Infectious diseases | Development agreement |
| 2017-09-17 | Merck&Co (USA - NJ) Zymeworks (Canada) | bispecific antibody therapeutic candidates generated through use of the Azymetric™ platform | development - licensing - commercialisation | undisclosed | Milestone | |
| 2017-09-14 | Daiichi Sankyo (Japan) The University of Texas MD Anderson Cancer Center (USA - TX) | quizartinib, DS-3032, DS-3201, and PLX51107 | acute myeloid leukemia (AML) | development | Cancer - Oncology | Development agreement |
| 2017-09-13 | Onxeo (France) Monopar Therapeutics (USA - IL) | Validive® (clonidine mucoadhesive buccal tablet) | severe oral mucositis induced by radiotherapy or chemotherapy in patients suffering from head and neck cancer | licensing | Cancer - Oncology | Licensing agreement |
| 2017-09-12 | Alexion Pharmaceuticals (USA - CT) | restructuring | Rare diseases - Genetic diseases | Restructuring | ||
| 2017-09-12 | TiGenix (Belgium) | head of medical department (US), director | nomination | Autoimmune diseases – Inflammatory diseases - Cardiovascular diseases | Nomination | |
| 2017-09-11 | Teva Pharmaceutical (Israel) | president and chief executive officer | nomination | Nomination | ||
| 2017-09-11 | Allergy Therapeutics (UK) | clinical director, head of clinical science, senior pharmaceutical physician | nomination | Allergic diseases | Nomination | |
| 2017-09-07 | Adaptimmune (UK) GSK (UK) | NY-ESO SPEAR T-cell therapy program including GSK3377794 | synovial sarcoma, myxoid round cell liposarcoma | licensing | Cancer - Oncology | Exercise of an option agreement |
| 2017-09-07 | Cell Therapy Catapult (UK) TrakCel (UK) | needle-to-needle supply chain management platform | collaboration | Technology - Services | Collaboration agreement | |
| 2017-09-07 | Eli Lilly (USA - IN) | restructuring | Restructuring | |||
| 2017-09-07 | Abivax (France) Evotec (Germany) | small molecules for the treatment of multiple serious viral infectious diseases | viral infectious diseases | development | Infectious diseases | Development agreement |
| 2017-09-06 | Pharmaxis (Australia) Synairgen (UK) | selective inhibitor to the lysyl oxidase type 2 enzyme (LOXL2) | idiopathic pulmonary fibrosis | R&D - research | Lung diseases - Respiratory diseases - Rare diseases | R&D agreement |
| 2017-09-05 | Boehringer Ingelheim (Germany) Inventiva (France) | new medicines for the treatment of idiopathic pulmonary fibrosis | idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases | research - R&D - licensing | Lung diseases - Respiratory diseases - Rare diseases - Fibrotic diseases | Exercise of an option agreement |
| 2017-09-05 | Portola Pharmaceuticals (USA - CA) Lonza (Switzerland) | AndexXa®(US)/ IndexXa™ (EU) | production - manufacturing | Production agreement | ||
| 2017-09-05 | TiGenix (Belgium) | manufacturing facility in Madrid | validation of a production plant | Autoimmune diseases - Inflammatory diseases | Validation of a production plant |
